ESG vs GLP-1 medication: mechanism, trial numbers, what happens when you stop, cost structure and four real-world scenarios — including planning an off-ramp. YOUNIFY Bangkok.
Contents
Key Takeaways
- ESG vs GLP-1: which first has no single answer that fits everyone. As of writing, no head-to-head randomised controlled trial comparing endoscopic sleeve gastroplasty with GLP-1 receptor agonist medication has been completed and published in full; comparative studies are still under way. What decides the starting point is your weight goal, the time frame you can commit to, the health conditions you carry alongside excess weight, and your long-term plan for three to five years from now.
- This guide from YOUNIFY's medical team lays out both paths side by side: mechanism, trial numbers with their sources, what happens when treatment stops, cost structure, and the questions worth raising with your medical team in four common situations. If the procedure itself is new to you, start with our main ESG guide.
The two approaches act on different things
GLP-1 receptor agonists, whose widely used generic names are semaglutide and tirzepatide (which acts at both the GLP-1 and GIP receptors), work at the level of hormones and satiety signalling. They slow gastric emptying, reduce appetite, and quieten food-related preoccupation. The effect lasts while the medication is present in the body, which makes this a continuing treatment by design.
ESG (endoscopic sleeve gastroplasty) is performed through the mouth with an endoscope and a dedicated suturing device that folds and stitches the stomach wall from the inside into a narrower, tube-like shape. International practice-standard consensus describes a reduction in gastric volume of around 70%, with no stomach tissue removed, no abdominal incisions, and no device left in the body. What changes is the capacity of the stomach itself, so the effect stays without ongoing medication.
That single difference drives almost every row in the table below: one approach changes the signal telling you to eat less, the other changes the space available for food.
ESG vs GLP-1: side-by-side comparison
| Factor | ESG (endoscopic suturing) | GLP-1 receptor agonist medication |
|---|---|---|
| Mechanism | Stomach wall folded and sutured from within, reducing gastric volume by around 70% (FITE-1 practice-standard consensus) | Acts on hormonal and satiety signalling; slows gastric emptying and reduces appetite |
| Treatment format | A single procedure, performed through the mouth; most patients go home the same day | Ongoing injections (typically weekly) under prescription and monitoring by the prescribing physician, with stepwise dose escalation |
| Weight numbers from trials | MERIT (Lancet 2022, RCT): 13.6% total body weight loss at 52 weeks vs 0.8% in controls | STEP-1 (NEJM 2021, RCT): −14.9% weight change at 68 weeks on semaglutide 2.4 mg (placebo −2.4%) · SURMOUNT-1 (NEJM 2022, RCT): around 20.9% at 72 weeks on tirzepatide 15 mg (placebo around 3.1%) |
| Longer-term follow-up data | Five-year follow-up: mean total body weight loss of 15.9%, with 61% still maintaining ≥10% TBWL at year five (Clin Gastroenterol Hepatol 2021) | Effect persists while treatment continues; data after discontinuation point towards regain (see next row) |
| What happens when you stop | There is no equivalent "stopping point"; the sutures stay. Gastric capacity may relax somewhat over time, so behavioural follow-through still matters | An evidence review in *eClinicalMedicine* 2026 reports that roughly two-thirds of lost weight is typically regained within a year of stopping, with cardiometabolic measures moving back towards baseline |
| Common side effects | Nausea, abdominal pain and vomiting in the first two to three days; a meta-analysis reports a pooled serious adverse event rate of 2.2% (95% CI 1.6–3.1) | Gastrointestinal symptoms are the most commonly reported group: nausea, vomiting, diarrhoea and constipation, usually most noticeable during dose escalation |
| Cost structure | One upfront cost followed by follow-up care. At YOUNIFY, from THB 490,000 | A recurring monthly cost structure for as long as treatment continues, with no predefined end point; the total depends on how long you stay on it |
| Future flexibility | No stomach tissue removed; in many cases it can be adjusted or revised later, and other options remain open | Dose can be adjusted, the agent changed, or treatment stopped as assessed by the prescribing physician, so highly flexible in the short term |
| Who it tends to suit | People who want a change that stays without ongoing medication, people who cannot tolerate medication side effects, or people planning for life after stopping (assessed individually by the medical team) | People who want to start without a procedure, people whose metabolic indications the prescribing physician judges suitable, and people prepared for continuing treatment |
| What must accompany either | The 2024 ASGE–ESGE guideline states that endoscopic bariatric therapy is used alongside lifestyle modification | Dietary change, muscle-mass preservation and follow-up with the prescribing physician belong in the plan from day one |
⚠️ Why these two sets of numbers cannot be compared directly
The table above is easy to read as a scoreboard, and methodologically that reading does not hold. Every figure comes from a different study, with a different starting population, a different follow-up duration, and a different outcome measure. MERIT enrolled people with class 1 and class 2 obesity and reported total body weight loss at 52 weeks. STEP-1 and SURMOUNT-1 recruited to their own criteria and reported percentage weight change at 68 and 72 weeks respectively. Lining up 13.6%, 14.9% and 20.9% side by side measures three things with three different rulers.
More to the point: no head-to-head randomised controlled trial of these two approaches has been completed and published in full. Comparative studies remain in progress. For that reason YOUNIFY's medical team does not conclude that either approach is superior. We use these numbers only to describe what each option has shown within its own context. What suits you comes from an individual assessment, not from ranking figures.
For our own clinic claim we use one consistent wording: ESG typically achieves around 15–18% of body weight over one year; individual results may vary.
The question that actually decides the plan: what happens when you stop
The question patients ask most often in 2026 is no longer whether the medication works; randomised trials have answered that for the period during which it is taken. The real question is what the plan is afterwards.
An evidence review published in *eClinicalMedicine* (Lancet Discovery Science) in 2026 reports two things worth knowing before starting, rather than after:
- Up to 65% of people taking GLP-1 medication discontinue within one year for a mix of reasons including side effects, ongoing cost, access, and a sense of having reached the goal.
- Roughly two-thirds of the weight lost is typically regained within one year of stopping, with the cardiometabolic improvements gained during treatment tending to reverse alongside it.
None of this means the medication is a poor choice. It works during use, and for many people it is the most appropriate option at that point in their life. What the data argue for is deciding the long-term plan on day one: either continuing treatment long term while accepting the cost structure and monitoring that come with it, or having something ready for the day it stops.
Important: starting, adjusting or stopping any weight-management medication must be done under the care of the prescribing physician. This article does not advise anyone to stop medication and is not a substitute for the advice of the doctor treating you.
The "off-ramp" concept
A term appearing more often in obesity medicine right now is the off-ramp: planning in advance what will hold the result in place when medication stops.
The ATTAIN study, presented at Digestive Disease Week in May 2026, followed 59 participants who had discontinued GLP-1 therapy. The group receiving ESG alongside lifestyle modification reached 17% total body weight loss at 12 months, compared with 0.1% in the lifestyle-only group. Mean BMI fell from 38 to 32, and no serious adverse events were reported in either group.
⚠️ Read these numbers carefully: ATTAIN is preliminary data presented at a scientific meeting and has not yet been peer reviewed and published in full. The participant number is small and long-term follow-up is not yet available. It is a signal worth factoring into planning, not a settled conclusion. We include it because it addresses the question patients ask most, not because it is the strongest evidence available.
Four real-world situations, and what to raise with your medical team
The guidance below is not a set of instructions. It is a list of questions that will make your first consultation more useful.
1. You have not tried any treatment yet
No medication, no procedure. The starting point under the 2024 ASGE–ESGE guideline is structured, supervised lifestyle modification, which underpins every option that follows. The same guideline positions endoscopic bariatric therapy for people with a BMI of 30 or above, or a BMI of 27.0–29.9 with at least one obesity-related condition.
What to raise: where my BMI and comorbidities sit against those criteria · what a realistic weight goal looks like for me · if I start with medication, what is the plan for years two and three · if I start with a procedure, what preparation and follow-up does it involve
2. You are on medication, it is working, and the cost is manageable
The most straightforward case: something that is working does not need changing. Discuss continuation and monitoring with your prescribing physician. What is worth adding is a prepared answer for the day circumstances change, whether that turns out to be side effects, cost, or access.
What to raise: what my long-term medication plan looks like · what the contingency is if I ever need to stop · how to protect muscle mass and nutrition meanwhile, so that lean tissue is not lost alongside fat
3. You are on medication but the side effects or the cost are unsustainable
This group is larger than most people assume, and it is a large part of why 65% discontinue within a year. The greatest risk here is stopping unilaterally, without discussing it with the prescribing physician and without anything in place afterwards.
What to raise: whether a dose adjustment or a change in approach could ease the side effects (ask the prescribing physician first, always) · if a joint decision is made to stop, how and when to do so · whether I meet the criteria for ESG, and how to sequence stopping medication against a procedure
4. You lost weight before and it came back
Whether the regain followed stopping medication, a weight-loss programme, or self-directed lifestyle change, the first step is not choosing a new method. It is identifying what drove the regain: returning hunger, portion sizes creeping upward, loss of muscle mass, or sleep and stress factors. Each cause leads to a different plan.
What to raise: which mechanism drove the regain in my case · whether body composition testing would clarify the muscle-to-fat picture · what options remain given my history · read more in long-term results after ESG
Can the two be used together?
This question comes up more and more, and the honest answer is that approaches are being studied, but the evidence remains limited. Studied approaches include medication for early weight reduction before a procedure in selected cases, medication added after a procedure when results fall short of target, and the procedure used as an off-ramp after stopping medication, as in ATTAIN.
What does not yet exist is a large body of data indicating which sequence suits whom, over what period, and with what long-term outcome. Combining them is therefore an individual decision made by the medical team, based on history, comorbidities, side effects previously experienced, and personal goals, and always coordinated with your prescribing physician if you are currently on treatment.
What does not change, whichever path you take
Both are tools, not substitutes for self-care. The 2024 ASGE–ESGE guideline is explicit that endoscopic bariatric therapy is used alongside lifestyle modification rather than in place of it, and the same principle applies to medication. Either path needs an eating plan that works in real daily life, attention to protein and muscle mass, consistent movement, and scheduled follow-up with the medical team.
The element people underestimate most is follow-up during the first year, the period when both approaches show their clearest effect and when new habits are actually set.
In summary
The shortest honest answer: there is no single right answer, and no completed head-to-head randomised trial comparing these two paths. GLP-1 medication works during use and is a sensible starting point for many people. ESG produces a change that stays without ongoing medication, and a growing number of people are considering it specifically as a plan for after medication stops.
The question worth asking is not which is better, but what my plan looks like three years from now, and which option actually gets me there. At YOUNIFY, the medical team assesses BMI, comorbidities, treatment history and goals before recommending an approach. If you are currently on medication, we will always have you consult your prescribing physician in parallel.
Frequently Asked Questions
Which is better, ESG or GLP-1 medication?
No head-to-head randomised controlled trial of these two approaches has been completed and published in full, so the question cannot be answered that way. The figures in circulation come from different studies with different starting populations and outcome measures. What decides is your goal, time frame, comorbidities and long-term plan, which an assessment by the medical team can clarify.
If I stop GLP-1 medication, will the weight come back?
An evidence review in *eClinicalMedicine* 2026 reports that roughly two-thirds of the weight lost is typically regained within a year of stopping, with cardiometabolic measures reversing alongside it, and that up to 65% of users discontinue within one year. This is why the long-term plan belongs at the start of treatment rather than at the point of stopping.
Should I stop my medication and have ESG instead?
This article does not advise anyone to stop medication. Starting, adjusting or stopping treatment must happen under the care of the prescribing physician. If you are considering it, speak with your prescribing physician first, then review eligibility criteria and timing with the medical team handling the procedure.
Is there evidence that ESG helps after stopping GLP-1?
There is preliminary evidence. The ATTAIN study presented at DDW in May 2026 (59 participants) reported 17% total body weight loss at 12 months in the group receiving ESG with lifestyle modification, compared with 0.1% in the lifestyle-only group, with no serious adverse events. This is preliminary data presented at a scientific meeting and has not yet been peer reviewed and published in full, so it is not a settled conclusion.
Can I take medication and have ESG as well?
Approaches are being studied, including medication before a procedure and medication added afterwards, but the evidence remains limited. Combining them is an individual decision made by the medical team, always coordinated with your prescribing physician.
How do the costs compare?
The structure differs more than the numbers. ESG is an upfront cost followed by follow-up care; at YOUNIFY, from THB 490,000. Medication is a recurring monthly cost for as long as treatment continues, so the total depends on duration. For the procedure side, see ESG cost and value and the Thailand cost guide.
Do I meet the criteria for ESG?
The 2024 ASGE–ESGE guideline positions endoscopic bariatric therapy for people with a BMI of 30 or above, or a BMI of 27.0–29.9 with at least one obesity-related condition, alongside lifestyle modification. The actual decision requires history, physical examination and a diagnostic gastroscopy. Full criteria are in who is suitable for ESG.
References
- Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial (Lancet, 2022)
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (N Engl J Med, 2021)
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (N Engl J Med, 2022)
- Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity (Clin Gastroenterol Hepatol, 2021)
- Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis (Clin Gastroenterol Hepatol, 2020)
- Weight maintenance after discontinuation of GLP-1 therapies (eClinicalMedicine, 2026)
- ASGE–ESGE guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity (Gastrointest Endosc, 2024)
- Establishing standards of practice for endoscopic sleeve gastroplasty: a global expert consensus using a modified Delphi method (FITE-1) (Gastrointest Endosc, 2025)
- ATTAIN — endoscopic sleeve gastroplasty after GLP-1 discontinuation ((ข้อมูลเบื้องต้นจากที่ประชุมวิชาการ ยังไม่ผ่านการตรวจทานโดยผู้ทรงคุณวุฒิฉบับเต็ม), 2026)
Medical Note
This article is for general information and does not replace medical examination, diagnosis, or treatment. If symptoms are severe, changing quickly, or urgent, seek medical care promptly.
Individual results may vary. Please consult a doctor before treatment.
Want to know which care plan fits you?
Share your symptoms, health history, medications or prior procedures, and personal goals. Our team can help arrange a medical assessment.
Consult YOUNIFY Clinic